<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102631">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02063360</url>
  </required_header>
  <id_info>
    <org_study_id>AI438-020</org_study_id>
    <nct_id>NCT02063360</nct_id>
  </id_info>
  <brief_title>DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)</brief_title>
  <official_title>Open-Label, Single-Sequence Study to Evaluate the Pharmacokinetic Interaction of BMS-663068 With Darunavir/Ritonavir and/or Etravirine in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if there is an interaction in healthy subjects
      taking BMS-663068 with Darunavir/Ritonavir and/or Etravirine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Brief title: drug-drug interaction (DDI)

      Primary Purpose: Other : Phase 1 Clinical Pharmacology drug interaction study in healthy
      subjects
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of BMS-626529</measure>
    <time_frame>20 timepoints up to day 26</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve in 1 dosing interval (AUC(TAU)) of BMS-626529</measure>
    <time_frame>20 timepoints up to day 26</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) for BMS-626529, DRV, RTV, and ETR</measure>
    <time_frame>Up to day 26 (20 timepoints for BMS-626529, 24 timepoints for DRV, RTV and ETR)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at 12 hours (C12) for BMS-626529, DRV, RTV, and ETR</measure>
    <time_frame>Up to day 26 (20 timepoints for BMS-626529, 24 timepoints for DRV, RTV and ETR)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed plasma concentration (Ctrough) for BMS-626529, DRV, RTV, and ETR</measure>
    <time_frame>Up to day 26 (20 timepoints for BMS-626529, 24 timepoints for DRV, RTV and ETR)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for DRV, RTV, and ETR</measure>
    <time_frame>24 timepoints up to 26 day</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(TAU) for DRV, RTV, and ETR</measure>
    <time_frame>24 timepoints up to 26 day</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability endpoints include incidence of adverse event (AEs), serious adverse event (SAEs), AEs leading to discontinuation, deaths, marked laboratory abnormalities, and abnormalities in vital signs, physical examination, and 12-lead ECGs</measure>
    <time_frame>Up to day 27</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>Cohort 1: BMS-663068+DRV/RTV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26
Tablet DRV 600mg / RTV 100mg orally orally twice daily on days 7-16</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: BMS-663068+ETR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26
Tablet ETR 200mg orally orally twice daily on days 7-16</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: BMS-663068+DRV/RTV+ETR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26
Tablet DRV 600mg / RTV 100mg and ETR 200mg orally orally twice daily on days 7-16</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-663068</intervention_name>
    <arm_group_label>Cohort 1: BMS-663068+DRV/RTV</arm_group_label>
    <arm_group_label>Cohort 2: BMS-663068+ETR</arm_group_label>
    <arm_group_label>Cohort 3: BMS-663068+DRV/RTV+ETR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir (DRV)</intervention_name>
    <arm_group_label>Cohort 1: BMS-663068+DRV/RTV</arm_group_label>
    <arm_group_label>Cohort 3: BMS-663068+DRV/RTV+ETR</arm_group_label>
    <other_name>Prezista</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir (RTV)</intervention_name>
    <arm_group_label>Cohort 1: BMS-663068+DRV/RTV</arm_group_label>
    <arm_group_label>Cohort 3: BMS-663068+DRV/RTV+ETR</arm_group_label>
    <other_name>Norvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etravirine (ETR)</intervention_name>
    <arm_group_label>Cohort 2: BMS-663068+ETR</arm_group_label>
    <arm_group_label>Cohort 3: BMS-663068+DRV/RTV+ETR</arm_group_label>
    <other_name>Intelence</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Healthy subjects with no clinically significant deviation from normal in medical
             history, physical examination findings, 12-lead ECG measurements, and clinical
             laboratory tests

          -  Women of childbearing potential (WOCBP) allowed. Must be practicing highly effective
             methods of contraception

        Exclusion Criteria:

          -  Any significant acute or chronic medical condition

          -  Unable to tolerate oral medications

          -  Inability to be venipunctured and/or tolerate venous access

          -  Current or recent  (within 3 months of dosing) gastrointestinal disease

          -  Abnormal liver function test
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 13, 2014</lastchanged_date>
  <firstreceived_date>February 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
